Skip to main content
Top
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Breast Cancer | Research

Notch3 restricts metastasis of breast cancers through regulation of the JAK/STAT5A signaling pathway

Authors: Min-Na Chen, Ze-Xuan Fang, Zheng Wu, Jing-Wen Bai, Rong-Hui Li, Xiao-Fen Wen, Guo-Jun Zhang, Jing Liu

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Purpose

To explore the potential role of signal transducer and activator of transcription 5A (STAT5A) in the metastasis of breast cancer, and its mechanism of regulation underlying.

Methods and results

TCGA datasets were used to evaluate the expression of STAT5A in normal and different cancerous tissues through TIMER2.0, indicating that STAT5A level was decreased in breast cancer tissues compared with normal ones. Gene Set Enrichment Analysis predicted that STAT5A was associated with the activation of immune cells and cell cycle process. We further demonstrated that the infiltration of immune cells was positively associated with STAT5A level. Influorescence staining revealed the expression and distribution of F-actin was regulated by STAT5A, while colony formation assay, wound healing and transwell assays predicted the inhibitory role of STAT5A in the colony formation, migratory and invasive abilities in breast cancer cells. In addition, overexpression of the Notch3 intracellular domain (N3ICD), the active form of Notch3, resulted in the increased expression of STAT5A. Conversely, silencing of Notch3 expression by siNotch3 decreased STAT5A expression, supporting that STAT5A expression is positively associated with Notch3 in human breast cancer cell lines and breast cancer tissues. Mechanistically, chromatin immunoprecipitation showed that Notch3 was directly bound to the STAT5A promoter and induced the expression of STAT5A. Moreover, overexpressing STAT5A partially reversed the enhanced mobility of breast cancer cells following Notch3 silencing. Low expression of Notch3 and STAT5A predicted poorer prognosis of patients with breast cancer.

Conclusion

The present study demonstrates that Notch3 inhibits metastasis in breast cancer through inducing transcriptionally STAT5A, which was associated with tumor-infiltrating immune cells, providing a novel strategy to treat breast cancer.
Appendix
Available only for authorised users
Literature
3.
go back to reference Raman D, et al. Breast cancer: a molecular and redox snapshot. Antioxid Redox Signal. 2016;25(6):337–70.PubMedCrossRef Raman D, et al. Breast cancer: a molecular and redox snapshot. Antioxid Redox Signal. 2016;25(6):337–70.PubMedCrossRef
5.
go back to reference Pastushenko I, Blanpain C. EMT transition states during tumor progression and metastasis. Trends Cell Biol. 2019;29(3):212–26.PubMedCrossRef Pastushenko I, Blanpain C. EMT transition states during tumor progression and metastasis. Trends Cell Biol. 2019;29(3):212–26.PubMedCrossRef
7.
go back to reference Babaei G, Aziz SG, Jaghi NZZ. EMT, cancer stem cells and autophagy; the three main axes of metastasis. Biomed Pharmacother. 2021;133:110909.PubMedCrossRef Babaei G, Aziz SG, Jaghi NZZ. EMT, cancer stem cells and autophagy; the three main axes of metastasis. Biomed Pharmacother. 2021;133:110909.PubMedCrossRef
9.
go back to reference Alexander CM. The wnt signaling landscape of mammary stem cells and breast tumors. Prog Mol Biol Transl Sci. 2018;153:271–98.PubMedCrossRef Alexander CM. The wnt signaling landscape of mammary stem cells and breast tumors. Prog Mol Biol Transl Sci. 2018;153:271–98.PubMedCrossRef
11.
go back to reference Wakao H, Gouilleux F, Groner B. Mammary gland factor (MGF) is a novel member of the cytokine regulated transcription factor gene family and confers the prolactin response. EMBO J. 1995;14(4):854–5.PubMedPubMedCentralCrossRef Wakao H, Gouilleux F, Groner B. Mammary gland factor (MGF) is a novel member of the cytokine regulated transcription factor gene family and confers the prolactin response. EMBO J. 1995;14(4):854–5.PubMedPubMedCentralCrossRef
12.
go back to reference Furth PA, et al. Signal transducer and activator of transcription 5 as a key signaling pathway in normal mammary gland developmental biology and breast cancer. Breast Cancer Res. 2011;13(5):220.PubMedPubMedCentralCrossRef Furth PA, et al. Signal transducer and activator of transcription 5 as a key signaling pathway in normal mammary gland developmental biology and breast cancer. Breast Cancer Res. 2011;13(5):220.PubMedPubMedCentralCrossRef
13.
go back to reference Liu X, et al. Stat5a is mandatory for adult mammary gland development and lactogenesis. Genes Dev. 1997;11(2):179–86.PubMedCrossRef Liu X, et al. Stat5a is mandatory for adult mammary gland development and lactogenesis. Genes Dev. 1997;11(2):179–86.PubMedCrossRef
14.
go back to reference Hachim IY, et al. A favorable role of prolactin in human breast cancer reveals novel pathway-based gene signatures indicative of tumor differentiation and favorable patient outcome. Hum Pathol. 2016;53:142–52.PubMedCrossRef Hachim IY, et al. A favorable role of prolactin in human breast cancer reveals novel pathway-based gene signatures indicative of tumor differentiation and favorable patient outcome. Hum Pathol. 2016;53:142–52.PubMedCrossRef
15.
go back to reference Tran TH, et al. Loss of nuclear localized parathyroid hormone-related protein in primary breast cancer predicts poor clinical outcome and correlates with suppressed stat5 signaling. Clin Cancer Res. 2018;24(24):6355–66.PubMedCrossRef Tran TH, et al. Loss of nuclear localized parathyroid hormone-related protein in primary breast cancer predicts poor clinical outcome and correlates with suppressed stat5 signaling. Clin Cancer Res. 2018;24(24):6355–66.PubMedCrossRef
16.
go back to reference Wang W, et al. miR-100 maintains phenotype of tumor-associated macrophages by targeting mTOR to promote tumor metastasis via Stat5a/IL-1ra pathway in mouse breast cancer. Oncogenesis. 2018;7(12):97.PubMedPubMedCentralCrossRef Wang W, et al. miR-100 maintains phenotype of tumor-associated macrophages by targeting mTOR to promote tumor metastasis via Stat5a/IL-1ra pathway in mouse breast cancer. Oncogenesis. 2018;7(12):97.PubMedPubMedCentralCrossRef
18.
go back to reference Sinha S, et al. Mucuna pruriens (L.) DC chemo sensitize human breast cancer cells via downregulation of prolactin-mediated JAK2/STAT5A signaling. J Ethnopharmacol. 2018;217:23–35.PubMedCrossRef Sinha S, et al. Mucuna pruriens (L.) DC chemo sensitize human breast cancer cells via downregulation of prolactin-mediated JAK2/STAT5A signaling. J Ethnopharmacol. 2018;217:23–35.PubMedCrossRef
19.
go back to reference Liu J, et al. Notch signaling in the regulation of stem cell self-renewal and differentiation. Curr Top Dev Biol. 2010;92:367–409.PubMedCrossRef Liu J, et al. Notch signaling in the regulation of stem cell self-renewal and differentiation. Curr Top Dev Biol. 2010;92:367–409.PubMedCrossRef
20.
21.
go back to reference Dou XW, et al. Notch3 maintains luminal phenotype and suppresses tumorigenesis and metastasis of breast cancer via trans-activating estrogen receptor-alpha. Theranostics. 2017;7(16):4041–56.PubMedPubMedCentralCrossRef Dou XW, et al. Notch3 maintains luminal phenotype and suppresses tumorigenesis and metastasis of breast cancer via trans-activating estrogen receptor-alpha. Theranostics. 2017;7(16):4041–56.PubMedPubMedCentralCrossRef
22.
go back to reference Bhat V, et al. Notch-induced expression of FZD7 requires noncanonical NOTCH3 signaling in human breast epithelial cells. Stem Cells Dev. 2016;25(7):522–9.PubMedCrossRef Bhat V, et al. Notch-induced expression of FZD7 requires noncanonical NOTCH3 signaling in human breast epithelial cells. Stem Cells Dev. 2016;25(7):522–9.PubMedCrossRef
23.
go back to reference Lin HY, et al. Notch3 inhibits epithelial-mesenchymal transition in breast cancer via a novel mechanism, upregulation of GATA-3 expression. Oncogenesis. 2018;7(8):59.PubMedPubMedCentralCrossRef Lin HY, et al. Notch3 inhibits epithelial-mesenchymal transition in breast cancer via a novel mechanism, upregulation of GATA-3 expression. Oncogenesis. 2018;7(8):59.PubMedPubMedCentralCrossRef
24.
go back to reference Zhang YQ, et al. Notch3 inhibits cell proliferation and tumorigenesis and predicts better prognosis in breast cancer through transactivating PTEN. Cell Death Dis. 2021;12(6):502.PubMedPubMedCentralCrossRef Zhang YQ, et al. Notch3 inhibits cell proliferation and tumorigenesis and predicts better prognosis in breast cancer through transactivating PTEN. Cell Death Dis. 2021;12(6):502.PubMedPubMedCentralCrossRef
25.
go back to reference Zhang X, et al. Notch3 inhibits epithelial-mesenchymal transition by activating Kibra-mediated Hippo/YAP signaling in breast cancer epithelial cells. Oncogenesis. 2016;5(11):e269.PubMedPubMedCentralCrossRef Zhang X, et al. Notch3 inhibits epithelial-mesenchymal transition by activating Kibra-mediated Hippo/YAP signaling in breast cancer epithelial cells. Oncogenesis. 2016;5(11):e269.PubMedPubMedCentralCrossRef
27.
28.
go back to reference Wen T, et al. Iron oxide nanoparticles induce reversible endothelial-to-mesenchymal transition in vascular endothelial cells at acutely non-cytotoxic concentrations. Part Fibre Toxicol. 2019;16(1):30.PubMedPubMedCentralCrossRef Wen T, et al. Iron oxide nanoparticles induce reversible endothelial-to-mesenchymal transition in vascular endothelial cells at acutely non-cytotoxic concentrations. Part Fibre Toxicol. 2019;16(1):30.PubMedPubMedCentralCrossRef
29.
go back to reference Schmidt JW, et al. Stat5 regulates the phosphatidylinositol 3-kinase/Akt1 pathway during mammary gland development and tumorigenesis. Mol Cell Biol. 2014;34(7):1363–77.PubMedPubMedCentralCrossRef Schmidt JW, et al. Stat5 regulates the phosphatidylinositol 3-kinase/Akt1 pathway during mammary gland development and tumorigenesis. Mol Cell Biol. 2014;34(7):1363–77.PubMedPubMedCentralCrossRef
30.
go back to reference Sakamoto K, et al. The Janus kinase 2 is required for expression and nuclear accumulation of cyclin D1 in proliferating mammary epithelial cells. Mol Endocrinol. 2007;21(8):1877–92.PubMedCrossRef Sakamoto K, et al. The Janus kinase 2 is required for expression and nuclear accumulation of cyclin D1 in proliferating mammary epithelial cells. Mol Endocrinol. 2007;21(8):1877–92.PubMedCrossRef
31.
go back to reference Ci YQ, Qiao JP, Han M. Molecular mechanisms and metabolomics of natural polyphenols interfering with breast cancer metastasis. Molecules. 2016;21(12):1634.PubMedPubMedCentralCrossRef Ci YQ, Qiao JP, Han M. Molecular mechanisms and metabolomics of natural polyphenols interfering with breast cancer metastasis. Molecules. 2016;21(12):1634.PubMedPubMedCentralCrossRef
32.
go back to reference Scully OJ, et al. Breast cancer metastasis. Cancer Genomics Proteomics. 2012;9(5):311–20.PubMed Scully OJ, et al. Breast cancer metastasis. Cancer Genomics Proteomics. 2012;9(5):311–20.PubMed
33.
go back to reference Liang Y, et al. Metastatic heterogeneity of breast cancer: Molecular mechanism and potential therapeutic targets. Semin Cancer Biol. 2020;60:14–27.PubMedCrossRef Liang Y, et al. Metastatic heterogeneity of breast cancer: Molecular mechanism and potential therapeutic targets. Semin Cancer Biol. 2020;60:14–27.PubMedCrossRef
34.
go back to reference Longworth A, et al. Genetics and pathological correlation of BRCA status in patients of Asian origin diagnosed with breast or ovarian cancer; a UK reference genetics laboratory study. Cancer Res. 2020;80(4):615. Longworth A, et al. Genetics and pathological correlation of BRCA status in patients of Asian origin diagnosed with breast or ovarian cancer; a UK reference genetics laboratory study. Cancer Res. 2020;80(4):615.
35.
go back to reference Kapoor PM, et al. Genome-wide gene-environment interaction study for breast cancer risk in European women, using data from the breast cancer association consortium. Genet Epidemiol. 2020;44(5):505–505. Kapoor PM, et al. Genome-wide gene-environment interaction study for breast cancer risk in European women, using data from the breast cancer association consortium. Genet Epidemiol. 2020;44(5):505–505.
36.
go back to reference Dunneram Y, Greenwood DC, Cade JE. Diet and risk of breast, endometrial and ovarian cancer: UK women’s cohort study. Br J Nutr. 2019;122(5):564–74.PubMedCrossRef Dunneram Y, Greenwood DC, Cade JE. Diet and risk of breast, endometrial and ovarian cancer: UK women’s cohort study. Br J Nutr. 2019;122(5):564–74.PubMedCrossRef
37.
go back to reference Zhang F, et al. Oncocyte membrane-camouflaged multi-stimuli-responsive nanohybrids for synergistic amplification of tumor oxidative stresses and photothermal enhanced cancer therapy. ACS Appl Mater Interfaces. 2022;14:40633–44.PubMedCrossRef Zhang F, et al. Oncocyte membrane-camouflaged multi-stimuli-responsive nanohybrids for synergistic amplification of tumor oxidative stresses and photothermal enhanced cancer therapy. ACS Appl Mater Interfaces. 2022;14:40633–44.PubMedCrossRef
38.
go back to reference Watson CJ. Stat transcription factors in mammary gland development and tumorigenesis. J Mammary Gland Biol Neoplasia. 2001;6(1):115–27.PubMedCrossRef Watson CJ. Stat transcription factors in mammary gland development and tumorigenesis. J Mammary Gland Biol Neoplasia. 2001;6(1):115–27.PubMedCrossRef
39.
go back to reference Dong J, et al. Genetic manipulation of individual somatic mammary cells in vivo reveals a master role of STAT5a in inducing alveolar fate commitment and lactogenesis even in the absence of ovarian hormones. Dev Biol. 2010;346(2):196–203.PubMedPubMedCentralCrossRef Dong J, et al. Genetic manipulation of individual somatic mammary cells in vivo reveals a master role of STAT5a in inducing alveolar fate commitment and lactogenesis even in the absence of ovarian hormones. Dev Biol. 2010;346(2):196–203.PubMedPubMedCentralCrossRef
40.
go back to reference Wheeler TT, et al. Stat5 phosphorylation status and DNA-binding activity in the bovine and murine mammary glands. Mol Cell Endocrinol. 2001;176(1–2):39–48.PubMedCrossRef Wheeler TT, et al. Stat5 phosphorylation status and DNA-binding activity in the bovine and murine mammary glands. Mol Cell Endocrinol. 2001;176(1–2):39–48.PubMedCrossRef
41.
42.
go back to reference Wu HT, et al. The transcriptional STAT3 is a potential target, whereas transcriptional STAT5A/5B/6 are new biomarkers for prognosis in human breast carcinoma. Oncotarget. 2017;8(22):36279–88.PubMedPubMedCentralCrossRef Wu HT, et al. The transcriptional STAT3 is a potential target, whereas transcriptional STAT5A/5B/6 are new biomarkers for prognosis in human breast carcinoma. Oncotarget. 2017;8(22):36279–88.PubMedPubMedCentralCrossRef
43.
go back to reference Ren S, et al. Loss of Stat5a delays mammary cancer progression in a mouse model. Oncogene. 2002;21(27):4335–9.PubMedCrossRef Ren S, et al. Loss of Stat5a delays mammary cancer progression in a mouse model. Oncogene. 2002;21(27):4335–9.PubMedCrossRef
44.
go back to reference Bratthauer GL, Strauss BL, Barner R. Reversed Expression of the JAK/STAT pathway related proteins prolactin receptor and STAT5a in normal and abnormal breast epithelial cells. Breast Cancer (Auckl). 2008;1:7–14.PubMed Bratthauer GL, Strauss BL, Barner R. Reversed Expression of the JAK/STAT pathway related proteins prolactin receptor and STAT5a in normal and abnormal breast epithelial cells. Breast Cancer (Auckl). 2008;1:7–14.PubMed
45.
go back to reference Wang Y, Cheng CH. ERalpha and STAT5a cross-talk: interaction through C-terminal portions of the proteins decreases STAT5a phosphorylation, nuclear translocation and DNA-binding. FEBS Lett. 2004;572(1–3):238–44.PubMedCrossRef Wang Y, Cheng CH. ERalpha and STAT5a cross-talk: interaction through C-terminal portions of the proteins decreases STAT5a phosphorylation, nuclear translocation and DNA-binding. FEBS Lett. 2004;572(1–3):238–44.PubMedCrossRef
46.
go back to reference Sultan AS, Brim H, Sherif ZA. Co-overexpression of Janus kinase 2 and signal transducer and activator of transcription 5a promotes differentiation of mammary cancer cells through reversal of epithelial-mesenchymal transition. Cancer Sci. 2008;99(2):272–9.PubMedCrossRef Sultan AS, Brim H, Sherif ZA. Co-overexpression of Janus kinase 2 and signal transducer and activator of transcription 5a promotes differentiation of mammary cancer cells through reversal of epithelial-mesenchymal transition. Cancer Sci. 2008;99(2):272–9.PubMedCrossRef
47.
48.
go back to reference Casetti L, et al. Differential contributions of STAT5A and STAT5B to stress protection and tyrosine kinase inhibitor resistance of chronic myeloid leukemia stem/progenitor cells. Cancer Res. 2013;73(7):2052–8.PubMedCrossRef Casetti L, et al. Differential contributions of STAT5A and STAT5B to stress protection and tyrosine kinase inhibitor resistance of chronic myeloid leukemia stem/progenitor cells. Cancer Res. 2013;73(7):2052–8.PubMedCrossRef
49.
go back to reference Cholez E, et al. Evidence for a protective role of the STAT5 transcription factor against oxidative stress in human leukemic pre-B cells. Leukemia. 2012;26(11):2390–7.PubMedCrossRef Cholez E, et al. Evidence for a protective role of the STAT5 transcription factor against oxidative stress in human leukemic pre-B cells. Leukemia. 2012;26(11):2390–7.PubMedCrossRef
50.
go back to reference Luo J, et al. 14, 15-EET induces breast cancer cell EMT and cisplatin resistance by up-regulating integrin alphavbeta3 and activating FAK/PI3K/AKT signaling. J Exp Clin Cancer Res. 2018;37(1):23.PubMedPubMedCentralCrossRef Luo J, et al. 14, 15-EET induces breast cancer cell EMT and cisplatin resistance by up-regulating integrin alphavbeta3 and activating FAK/PI3K/AKT signaling. J Exp Clin Cancer Res. 2018;37(1):23.PubMedPubMedCentralCrossRef
51.
go back to reference Li Y, et al. OSR1 phosphorylates the Smad2/3 linker region and induces TGF-beta1 autocrine to promote EMT and metastasis in breast cancer. Oncogene. 2021;40(1):68–84.PubMedCrossRef Li Y, et al. OSR1 phosphorylates the Smad2/3 linker region and induces TGF-beta1 autocrine to promote EMT and metastasis in breast cancer. Oncogene. 2021;40(1):68–84.PubMedCrossRef
54.
go back to reference Wu Y, et al. MicroRNA-488 inhibits proliferation and motility of tumor cells via downregulating FSCN1, modulated by Notch3 in breast carcinomas. Cell Death Dis. 2020;11(10):912.PubMedPubMedCentralCrossRef Wu Y, et al. MicroRNA-488 inhibits proliferation and motility of tumor cells via downregulating FSCN1, modulated by Notch3 in breast carcinomas. Cell Death Dis. 2020;11(10):912.PubMedPubMedCentralCrossRef
55.
56.
go back to reference Tang JZ, et al. Signal transducer and activator of transcription (STAT)-5A and STAT5B differentially regulate human mammary carcinoma cell behavior. Endocrinology. 2010;151(1):43–55.PubMedCrossRef Tang JZ, et al. Signal transducer and activator of transcription (STAT)-5A and STAT5B differentially regulate human mammary carcinoma cell behavior. Endocrinology. 2010;151(1):43–55.PubMedCrossRef
57.
58.
go back to reference Peck AR, et al. Low levels of Stat5a protein in breast cancer are associated with tumor progression and unfavorable clinical outcomes. Breast Cancer Res. 2012;14(5):R130.PubMedPubMedCentralCrossRef Peck AR, et al. Low levels of Stat5a protein in breast cancer are associated with tumor progression and unfavorable clinical outcomes. Breast Cancer Res. 2012;14(5):R130.PubMedPubMedCentralCrossRef
59.
go back to reference Zeng Y, et al. Inhibition of STAT5a by Naa10p contributes to decreased breast cancer metastasis. Carcinogenesis. 2014;35(10):2244–53.PubMedCrossRef Zeng Y, et al. Inhibition of STAT5a by Naa10p contributes to decreased breast cancer metastasis. Carcinogenesis. 2014;35(10):2244–53.PubMedCrossRef
60.
61.
go back to reference Liao Z, et al. Structure-based screen identifies a potent small molecule inhibitor of Stat5a/b with therapeutic potential for prostate cancer and chronic myeloid leukemia. Mol Cancer Ther. 2015;14(8):1777–93.PubMedPubMedCentralCrossRef Liao Z, et al. Structure-based screen identifies a potent small molecule inhibitor of Stat5a/b with therapeutic potential for prostate cancer and chronic myeloid leukemia. Mol Cancer Ther. 2015;14(8):1777–93.PubMedPubMedCentralCrossRef
62.
go back to reference Kaneshige A, et al. A selective small-molecule STAT5 PROTAC degrader capable of achieving tumor regression in vivo. Nat Chem Biol. 2023;19(6):703–11.PubMedCrossRef Kaneshige A, et al. A selective small-molecule STAT5 PROTAC degrader capable of achieving tumor regression in vivo. Nat Chem Biol. 2023;19(6):703–11.PubMedCrossRef
Metadata
Title
Notch3 restricts metastasis of breast cancers through regulation of the JAK/STAT5A signaling pathway
Authors
Min-Na Chen
Ze-Xuan Fang
Zheng Wu
Jing-Wen Bai
Rong-Hui Li
Xiao-Fen Wen
Guo-Jun Zhang
Jing Liu
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-11746-w

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine